CryoLife, Inc. P/Operating CF

P/Operating CF of CRY for past 10 years: annual, quarterly and twelve month trailing (TTM) including P/Operating CF growth rates and interactive chart. A valuation metric that measures the price of a stock compared to its operating cash flow per share. Operating cash flow (OCF) is the amount of cash generated by a company's normal business operations. It can be different from reported net income due to accrual accounting, that is expenses and revenues are recognized differently than cash is received. The cash going in and out of the business is what ultimately determines its financial health, so it's one of the most important metrics to watch. A low P/OCF ratio can indicate undervaluation, while a high one might mean the growth expectations around the company are elevated. P/OCF ratio can be compared to different companies in the same industry or to a company’s own historical valuation.


Highlights and Quick Summary

Current P/Operating CF of CryoLife, Inc. is 167.28 (as of December 30, 2020)
  • P/Operating CF for the quarter ending March 30, 2021 was -287.83 (a -272.07% decrease compared to previous quarter)
  • Year-over-year quarterly P/Operating CF increased by 35.86%
  • Annual P/Operating CF for 2020 was 167.28 (a -82.44% decrease from previous year)
  • Annual P/Operating CF for 2019 was 952.6 (a 1636.83% increase from previous year)
  • Annual P/Operating CF for 2018 was 54.85 (a -48.0% decrease from previous year)
Visit stockrow.com/CRY for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical P/Operating CF of CryoLife, Inc.

Most recent P/Operating CFof CRY including historical data for past 10 years.

Interactive Chart of P/Operating CF of CryoLife, Inc.

CryoLife, Inc. P/Operating CF for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 -287.83
2020 167.28 91.19 -211.86 240.09 167.28
2019 952.6 78.65 1520.11 912.01 952.6
2018 54.85 0.0 1354.23 -72.09 54.85
2017 105.48 272.69 -352.81 139.6 105.48
2016 119.97 63.93 85.37 236.57 119.97
2015 211.36 56.01 80.24 219.89 211.36
2014 64.83 107.87 85.85 -133.79 64.83
2013 54.56 25.98 32.62 -136.95 54.56
2012 21.05 30.25 45.76 83.42 21.05
2011 43.36 21.25 38.09 43.21 43.36
2010 21.62 44.57 24.97 21.62

Business Profile of CryoLife, Inc.

Sector: Healthcare
Industry: Medical Devices
CryoLife, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. It offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X prosthetic aortic and mitral heart valve, and On-X ascending aortic prosthesis; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita OPEN PLUS and E-vita OPEN NEO, a hybrid stent graft system. The company also provides E-xtra DESIGN ENGINEERING products for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, it offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; and cardiac laser therapy products, such as SolarGen 2100s Console and SoloGrip III disposable handpieces. Further, the company sells CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as offers pyrolytic carbon coating services to other medical device manufacturers. The company serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. CryoLife, Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.